Clinical trials to determine whether prazosin, a drug already widely used for common medical conditions, can prevent cytokine storms and severe disease in COVID-19 patients when given early after infection.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Bert VogelsteinResearch Location
United States of AmericaLead Research Institution
Johns Hopkins UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified